Radiopharmaceuticals - Aixial Group

We have been supporting complex Radiopharmaceutical (RP) trials on a global scale for over 10 years. Our focus is to make sure sponsors are comfortable and confident from the start, aware of potential risks, and realistic about results.

The only partner you need in RadioPharmaceuticals

We transform your synopsis into a fully rounded protocol with the maximum chance of success, carrying out detailed consideration, planning and management. Our team can bring everything together, ensuring the research and medical considerations match capabilities and local processes at site. Our Nuclear Medicine departmental experience and package of processes can be used for very specific studies. And we take the time to allocate the right team for you.

Phase I-III, including first-in-human

Oncology and rare diseases

Mono and combo therapy trials

USA, Europe, and APAC

Why work with us?

Helping you succeed in your project

10+

Years of radiotherapeutics experience

42 Study sizes up to 42 sites and 180 patients

81 Site relationships and over 570 patients

Aixial Group experts in Radiopharmaceuticals development

Development of a novel radiopharmaceutical agent through clinical evaluation is complex and spans multiple domains; CROs provide a crucial contribution in managing the continued growth of radiopharmaceuticals development globally. Aixial Group possess the necessary expertise to manage the unique complexities of developing a radiopharmaceutical product from the concept stage through to trial execution and approval. In addition to the factors outlined above, Aixial leverages longstanding relationships with our global and expansive network of nuclear medicine centers and specialist research sites to facilitate patient recruitment.

As a leading CRO in the radiopharmaceuticals market, Aixial offers the knowledge and infrastructure required to deliver successful outcomes in global trials involving radiopharmaceuticals.

Contact us for a feasibility analysis offered at no cost to kick-start your plans for your next radiopharmaceuticals trial. Read more.

Insights

Atomising cancer

Breakthrough — Radiopharmaceutical therapy represents a novel approach to treating cancer, utilising radioactive atoms to target and destroy malignant cells with precision, without affecting the patient’s healthy tissues. A field in which Aixial has emerged as a pioneer.

A Phase II Open -Label Safety and Efficacy Study of combination IP in patients with progressed advanced malignancies

Did you know that lung cancer is the most diagnosed cancer in the world? In 2022, it accounted for 12.4% of all new cancer cases and 18.7% of deaths. The 5-year survival rate for lung cancer has increased by 22% over the last 5 years due to advances in treatment. However, only 26% of cases are diagnosed at an early stage, when the survival rate is 61%.

Safety, Preliminary Efficacy and Pharmacokinetics of [IP] in Metastatic Castrate Resistant Prostate Cancer

Prostate cancer is on the increase globally, especially in men under the age of 50, and in 2022 there were 1.47 million new cases. The 5-year survival rate is close to 100%, largely thanks to advances in treatment and early detection.

Training and upskilling are part of our genes

Talents — The world of life sciences is vast and constantly evolving. It’s not enough to follow trends: you have to anticipate them, and to do that you need to bring together the best specialists. At Aixial Group, Stéphane Thérèse is well aware of this.

Breast Cancer and Aixial Group’s Expertise

In recognition of Breast Cancer Awareness Month, Ashley Hunter, Head of Strategic Development and Delivery, offers valuable insights on the importance of early detection, the latest advancements and ongoing challenges in breast cancer research, and how Aixial Group is actively supporting the fight against breast cancer.

Interview with Bastien Crouzet

“We provide high-level expertise in a niche and critical area across the entire clinical supply chain flow, from the planning of the initial drug substance manufacturing to the Investigational Product reconciliation/destruction.”

Radiopharmaceutical Trials